Torin 2

Name: Torin 2
Brand: MedChemExpress
SKU: HY-13002
Rating: 5.0 (17 reviews)

Cat. No.: HY-13002 Purity: 99.65%: Data Sheet
SDS

COA
Handling Instructions Technical Support

Solubility

In Vivo Dissolution Calculator

Torin 2 is an mTOR inhibitor with EC₅₀ of 0.25 nM for inhibiting cellular mTOR activity, and exhibits 800-fold selectivity over PI3K (EC₅₀: 200 nM). Torin 2 also inhibits DNA-PK with an IC₅₀ of 0.5 nM in the cell free assay. Torin 2 can suppress both mTORC1 and mTORC2.

For research use only. We do not sell to patients.

Torin 2 Chemical Structure

CAS No. : 1223001-51-1

Size	Price	Stock	Quantity

Free Sample (0.1 - 0.5 mg)		Apply Now
Solid + Solvent (Highly Recommended)
10 mM * 1 mL in DMSO ready for reconstitution	USD 79	In-stock	Estimated Time of Arrival: April 8
Solution
10 mM * 1 mL in DMSO	USD 83	In-stock	Estimated Time of Arrival: April 8
Solid
5 mg	USD 76	In-stock	Estimated Time of Arrival: April 8
10 mg	USD 127	In-stock	Estimated Time of Arrival: April 8
50 mg	USD 381	In-stock	Estimated Time of Arrival: April 8
100 mg	USD 566	In-stock	Estimated Time of Arrival: April 8
200 mg	USD 978	In-stock	Estimated Time of Arrival: April 8
500 mg		Get quote
1 g		Get quote

Get it by April 8 for select sizes. Order within 13 hrs 39 mins.

or Bulk Inquiry

* Please select Quantity before adding items.

Customer Review

Based on 17 publication(s) in Google Scholar

16 Publications Citing Use of MCE Torin 2

: Torin 2 purchased from MedChemExpress. Usage Cited in: Mol Cancer Ther. 2018 Dec;17(12):2676-2688. [Abstract]; The mTORC1/2 inhibitor Torin2 suppresses protein synthesis in the EW8 and TC71 Ewing sarcoma cell lines.

Featured Recommendations

•Related Screening Libraries:

•Related Small Molecules:

View All mTOR Isoform Specific Products:

View All Isoforms

mTOR mTORC1 mTORC2

Biological Activity
Protocol
Purity & Documentation
References
Customer Review

Description

IC₅₀ & Target^[1]^[4]

mTOR

2.81 nM (IC₅₀)

mTOR

0.25 nM (EC₅₀, Cell Assay)

mTORC1

mTORC2

DNA-PK

0.5 nM (IC₅₀)

p110γ

5.67 nM (IC₅₀)

PI3K-C2β

24.5 nM (IC₅₀)

PI3K-C2α

28.1 nM (IC₅₀)

hVps34

8.58 nM (IC₅₀)

PI3K

200 nM (EC₅₀, Cell Assay)

ΡΙ4Κβ

18.3 nM (IC₅₀)

Autophagy

Cellular Effect

Cell Line	Type	Value	Description	References
HCT-116	GI₅₀	32.19 nM Compound: Torin2	Growth inhibition of human HCT116 cells measured after 72 hrs by Celltiter-Glo assay Growth inhibition of human HCT116 cells measured after 72 hrs by Celltiter-Glo assay	[PMID: 32911078]
HeLa	IC₅₀	< 10 nM Compound: 15	Inhibition of N-terminally FLAG-tagged mTORC2 (unknown origin) expressed in human HeLa cells using S6K1 or Akt1 as substrate after 20 mins by immunoblotting assay Inhibition of N-terminally FLAG-tagged mTORC2 (unknown origin) expressed in human HeLa cells using S6K1 or Akt1 as substrate after 20 mins by immunoblotting assay	[PMID: 29211480]
HeLa	GI₅₀	97.95 nM Compound: Torin2	Growth inhibition of human HeLa cells measured after 72 hrs by Celltiter-Glo assay Growth inhibition of human HeLa cells measured after 72 hrs by Celltiter-Glo assay	[PMID: 32911078]
MOLM-13	IC₅₀	< 1 nM Compound: Torin2	Antiproliferative activity against human MOLM13 cells by Cell-Titer Glo assay Antiproliferative activity against human MOLM13 cells by Cell-Titer Glo assay	[PMID: 30370766]
MOLM-14	IC₅₀	< 1 nM Compound: Torin2	Antiproliferative activity against human MOLM14 cells by Cell-Titer Glo assay Antiproliferative activity against human MOLM14 cells by Cell-Titer Glo assay	[PMID: 30370766]
MV4-11	IC₅₀	< 1 nM Compound: Torin2	Antiproliferative activity against human MV4-11 cells by Cell-Titer Glo assay Antiproliferative activity against human MV4-11 cells by Cell-Titer Glo assay	[PMID: 30370766]
PC-3	EC₅₀	200 nM Compound: 3, Torin2	Inhibition of PI3Kalpha in human PC3 cells expressing Akt1 S473D mutant assessed as phosphorylation of Akt Thr308 by immunoblotting Inhibition of PI3Kalpha in human PC3 cells expressing Akt1 S473D mutant assessed as phosphorylation of Akt Thr308 by immunoblotting	[PMID: 21322566]
RD	CC₅₀	0.04 μM Compound: 1	Cytotoxicity against human RD cells incubated for 4 days by CellTiter-Glo luminescence assay Cytotoxicity against human RD cells incubated for 4 days by CellTiter-Glo luminescence assay	[PMID: 31082764]

In Vitro

Torin 2 is subject to further profiling against a panel of lipid kinases with IC₅₀s of 2.81 nM, 0.5 nM, 5.67 nM, 8.58 nM, 18.3 nM, 24.5 nM and 28.1 nM for mTOR, DNA-pK, p110γ, hVPS34, PI4Kβ, PI3K-C2β and PI3K-C2α, respectively. Torin 2 (Torin2) possesses a 250 pM EC₅₀ for inhibiting mTOR in cells while maintaining 800-fold cellular selectivity relative to inhibition of PI3K and most other protein kinases^[1]. Torin 2 (Torin2) exhibits potent biochemical and cellular activity against PIKK family kinases including ATM (EC₅₀ 28 nM), ATR (EC₅₀ 35 nM) and DNA-PK (EC₅₀ 118 nM). Torin 2 potently inhibits T308 of Akt, a direct substrate of PDK1 and an indirect substrate of PI3Ks, with an EC₅₀ of less than 10 nM^[2]. Torin-2 can suppress both mTORC1 and mTORC2^[4].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

Torin 2 exhibits good bioavailability and exposure and can maintain strong inhibition of mTOR activity in lung and liver to at least six hours after a single dose of 20 mg/kg. Torin 2 is easier to produce on scale and exhibits improved pharmacokinetic properties which should enable it use in vivo experiments^[1]. Torin 2 strongly suppresses pS6K(T389) and p4EBP1(T37/46) and partly suppresses pAkt(T308). Treatment of mice with AZD6244 at 25 mg/kg results in a profound inhibition of pERK. Combined administration of Torin 2 (40 mg/kg) and AZD6244 (25 mg/kg) demonstrates strong inhibition of all pharmacodynamics markers^[2]. Treatment with Torin 2 and Rapamycin induces IL-6 secretion by astrocytes and may contribute to the reduction of mechanical hypersensitivity after SCI. Torin1 and Torin 2 treatment increases IL-6 mRNA, suggesting that the PI3K-mTOR pathway is a negative regulator of IL-6 expression in astrocytes. Importantly, Torin 2 treatment does not show any cell toxicity, as no signs of cell death are observed by TUNEL assay or by detection of cleaved-caspase 3 by western blotting^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Molecular Weight

432.40

Formula

C₂₄H₁₅F₃N₄O

CAS No.

1223001-51-1

Appearance

Solid

Color

White to light yellow

SMILES

O=C1N(C2=C(C=C1)C=NC3=CC=C(C=C32)C4=CC=C(N=C4)N)C5=CC=CC(C(F)(F)F)=C5

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	1 year
	-20°C	6 months

Solvent & Solubility

In Vitro:

DMSO : 15.62 mg/mL (36.12 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

Preparing
Stock Solutions

Concentration Solvent Mass	1 mg	5 mg	10 mg

1 mM	2.3127 mL	11.5634 mL	23.1267 mL
5 mM	0.4625 mL	2.3127 mL	4.6253 mL
10 mM	0.2313 mL	1.1563 mL	2.3127 mL

View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 1 year; -20°C, 6 months. When stored at -80°C, please use it within 1 year. When stored at -20°C, please use it within 6 months.

Molarity Calculator
Dilution Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

This equation is commonly abbreviated as: C₁V₁ = C₂V₂

Concentration _(start)

Volume _(start)

Concentration _(final)

Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 1.56 mg/mL (3.61 mM); Clear solution

This protocol yields a clear solution of ≥ 1.56 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (15.6 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.

For the following dissolution methods, please prepare the working solution directly. It is recommended to prepare fresh solutions and use them promptly within a short period of time.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% 1-Methyl-2-pyrrolidinone 90% PEG300
Solubility: ≥ 2 mg/mL (4.63 mM); Clear solution

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

DMSO +

Tween-80 +

Saline

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.

The co-solvents required include: DMSO, PEG300/PEG400, Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Purity & Documentation

Purity: 99.65%

Select Batch:

Data Sheet (285 KB) SDS (251 KB)

COA (253 KB)LCMS (93 KB)

Handling Instructions (2659 KB)

References

[1]. Liu Q, et al. Discovery of 9-(6-aminopyridin-3-yl)-1-(3-(trifluoromethyl)phenyl)benzo[h][1,6]naphthyridin-2(1H)-one (Torin2) as a potent, selective, and orally available mammalian target of rapamycin (mTOR) inhibitor for treatment of cancer. J Med Chem. 2011 Mar 10;54(5):1473-80. [Content Brief]

[2]. Liu Q, et al. Characterization of Torin2, an ATP-competitive inhibitor of mTOR, ATM, and ATR. Cancer Res. 2013 Apr 15;73(8):2574-86. [Content Brief]

[3]. Codeluppi S, et al. Interleukin-6 secretion by astrocytes is dynamically regulated by PI3K-mTOR-calcium signaling. PLoS One. 2014 Mar 25;9(3):e92649. [Content Brief]

[4]. Wang X, et al. mTORC signaling in hematopoiesis. Int J Hematol. 2016 May;103(5):510-8. [Content Brief]

Cell Assay ^[2]	HCT116 cells are treated with 100 nM Torin 2 or AZD8055 for 1 hour before they are thoroughly washed out by 3×PBS and 1×DMEM medium. Then cells are incubated in DMEM medium for indicated time before they are lysed and collected using M-PER. Protein concentrations are measured and equal amount of proteins are loaded. Experiments are repeated three times and one set of results^[2]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.
Animal Administration ^[1]^[3]	Mice^[1] Six-week old male C57BL/6 mice are fasted overnight prior to Torin 2 treatment. The mice are treated with vehicle (for 10 h) or Torin 2 (20 mg/kg for 6h) via oral gavage and then re-fed 1 h prior to sacrifice (CO₂ asphyxiation). Liver and lung are collected and frozen on dry ice. The frozen tissue is thawed on ice and lysed by sonication in tissue lysis buffer (50 mM HEPES, pH 7.4, 40 mM NaCl, 2 mM EDTA, 1.5 mM sodium orthovanadate, 50 mM sodium fluoride, 10 mM sodium pyrophosphate, 10 mM sodium β-glycerophosphate, 0.1% SDS, 1.0% sodium deoxycholate, and 1.0% Triton, supplemented with protease inhibitor cocktail tablets). The concentration of clear lysate is measured using the Bradford assay and samples are subsequently normalized by protein content and analyzed by SDS-PAGE and immunoblotting. Rats^[3] Female rats (220 g) are group-housed 4 animals per cage, and kept on a 12-hour light/dark cycle with food and water ad libitum. Spinal cord injury is done with the Keck Center for Neurosciences impactor using a 10 g weight dropped from a height of 25 mm onto the dorsal surface of the exposed spinal cord. After recording BBB scores, withdrawal thresholds evoked by touch stimulus, and body weights for the first week post-injury, animals are divided into 5 treatment groups: naïve (N=4), sham (N=6), vehicle (N=6), Torin 2 (N=6), and Torin 2+Rapamycin (N=8). Torin 2 alone (4 mg/kg) or in combination with Rapamycin (1.5 mg/kg) is administered orally by gavage once a day starting at day 15 after injury and ending at day 29. In sham operated rats only the laminectomy is performed. MCE has not independently confirmed the accuracy of these methods. They are for reference only.
References	[1]. Liu Q, et al. Discovery of 9-(6-aminopyridin-3-yl)-1-(3-(trifluoromethyl)phenyl)benzo[h][1,6]naphthyridin-2(1H)-one (Torin2) as a potent, selective, and orally available mammalian target of rapamycin (mTOR) inhibitor for treatment of cancer. J Med Chem. 2011 Mar 10;54(5):1473-80. [Content Brief] [2]. Liu Q, et al. Characterization of Torin2, an ATP-competitive inhibitor of mTOR, ATM, and ATR. Cancer Res. 2013 Apr 15;73(8):2574-86. [Content Brief] [3]. Codeluppi S, et al. Interleukin-6 secretion by astrocytes is dynamically regulated by PI3K-mTOR-calcium signaling. PLoS One. 2014 Mar 25;9(3):e92649. [Content Brief] [4]. Wang X, et al. mTORC signaling in hematopoiesis. Int J Hematol. 2016 May;103(5):510-8. [Content Brief]

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg

DMSO	1 mM	2.3127 mL	11.5634 mL	23.1267 mL	57.8168 mL
	5 mM	0.4625 mL	2.3127 mL	4.6253 mL	11.5634 mL
	10 mM	0.2313 mL	1.1563 mL	2.3127 mL	5.7817 mL
	15 mM	0.1542 mL	0.7709 mL	1.5418 mL	3.8545 mL
	20 mM	0.1156 mL	0.5782 mL	1.1563 mL	2.8908 mL
	25 mM	0.0925 mL	0.4625 mL	0.9251 mL	2.3127 mL
	30 mM	0.0771 mL	0.3854 mL	0.7709 mL	1.9272 mL

Torin 2 Related Classifications

Keywords:

Torin 21223001-51-1Torin2Torin-2mTORDNA-PKAutophagyApoptosisMammalian target of RapamycinDNA-dependent protein kinaseInhibitorinhibitorinhibit

Your Recently Viewed Products:

Torin 2

Please select a local distributor ナミキ商事株式会社コスモ・バイオ株式会社
Product Name			Requested Quantity *
Applicant Name *			Salutation
Email Address *			Phone Number *
Department			Organization Name *
City			State
Country or Region *
Remarks

Product Name			Lot #
Applicant Name *			Email Address *
Phone Number			Department *
Organization Name *			Country or Region *
Remarks

Name
Email *

	Sorry, but the email address you supplied was invalid.

Torin 2

Customer Review

Torin 2 Related Antibodies

16 Publications Citing Use of MCE Torin 2

Featured Recommendations

•Related Screening Libraries:

•Related Small Molecules:

View All mTOR Isoform Specific Products:

Biological Activity

Protocol

Purity & Documentation

References

Customer Review

Torin 2 Related Antibodies

Molarity Calculator

Dilution Calculator

Complete Stock Solution Preparation Table

Torin 2 Related Classifications

Keywords:

Your Recently Viewed Products:

Customer Review

Request for HNMR Report

SAFETY DATA SHEET (SDS)

Request for HNMR Report